Heterogeneity of ORs between BRCA1 and BRCA2 were shown in ovarian (I2, 90.9%) and prostate cancer (I2, 77.4%) (Table 2).32 We also observed an association with lymphoma and lung cancer for BRCA1 and endometrial, cervical, kidney, and liver cancers for BRCA2 (Table 2). The gene discussed is BRCA1; the disease is prostate cancer.